The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1508
Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved lesinurad (Zurampic – Ironwood), a uric acid transporter 1 (URAT1) inhibitor, for adjunctive treatment of gout-associated hyperuricemia in patients whose serum uric acid levels fail to reach goal with xanthine oxidase inhibitor monotherapy.

STANDARD TREATMENT — Recent guidelines offer conflicting views on the benefits of monitoring serum uric acid levels and the appropriate use of urate-lowering therapy in patients with gout,1-3 but most expert clinicians still initially treat gout-associated hyperuricemia with a xanthine oxidase inhibitor such as allopurinol or febuxostat with the goal of reducing the serum uric acid level below 6.0 mg/dL (and preferably below 5.0 mg/dL). The uricosuric drug probenecid can be used for add-on therapy if target serum uric acid levels are not reached with a xanthine oxidase inhibitor alone or for initial therapy ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
Article code: 1508b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian